Marksans Pharma Limited

NSEI:MARKSANS Stock Report

Market Cap: ₹138.2b

Marksans Pharma Past Earnings Performance

Past criteria checks 1/6

Marksans Pharma has been growing earnings at an average annual rate of 19.7%, while the Pharmaceuticals industry saw earnings growing at 13.5% annually. Revenues have been growing at an average rate of 16% per year. Marksans Pharma's return on equity is 15.1%, and it has net margins of 14.6%.

Key information

19.7%

Earnings growth rate

17.4%

EPS growth rate

Pharmaceuticals Industry Growth17.5%
Revenue growth rate16.0%
Return on equity15.1%
Net Margin14.6%
Last Earnings Update30 Sep 2024

Recent past performance updates

Solid Earnings May Not Tell The Whole Story For Marksans Pharma (NSE:MARKSANS)

Jun 07
Solid Earnings May Not Tell The Whole Story For Marksans Pharma (NSE:MARKSANS)

Recent updates

Marksans Pharma Limited (NSE:MARKSANS) Stock Rockets 28% As Investors Are Less Pessimistic Than Expected

Nov 27
Marksans Pharma Limited (NSE:MARKSANS) Stock Rockets 28% As Investors Are Less Pessimistic Than Expected

Is Now The Time To Put Marksans Pharma (NSE:MARKSANS) On Your Watchlist?

Oct 24
Is Now The Time To Put Marksans Pharma (NSE:MARKSANS) On Your Watchlist?

Optimistic Investors Push Marksans Pharma Limited (NSE:MARKSANS) Shares Up 45% But Growth Is Lacking

Sep 21
Optimistic Investors Push Marksans Pharma Limited (NSE:MARKSANS) Shares Up 45% But Growth Is Lacking

Marksans Pharma Limited (NSE:MARKSANS) Stock Rockets 26% But Many Are Still Ignoring The Company

Jul 28
Marksans Pharma Limited (NSE:MARKSANS) Stock Rockets 26% But Many Are Still Ignoring The Company

Solid Earnings May Not Tell The Whole Story For Marksans Pharma (NSE:MARKSANS)

Jun 07
Solid Earnings May Not Tell The Whole Story For Marksans Pharma (NSE:MARKSANS)

Does Marksans Pharma (NSE:MARKSANS) Deserve A Spot On Your Watchlist?

May 31
Does Marksans Pharma (NSE:MARKSANS) Deserve A Spot On Your Watchlist?

Sentiment Still Eluding Marksans Pharma Limited (NSE:MARKSANS)

Feb 16
Sentiment Still Eluding Marksans Pharma Limited (NSE:MARKSANS)

Here's Why Marksans Pharma (NSE:MARKSANS) Has Caught The Eye Of Investors

Jan 26
Here's Why Marksans Pharma (NSE:MARKSANS) Has Caught The Eye Of Investors

We Think Marksans Pharma (NSE:MARKSANS) Can Manage Its Debt With Ease

Dec 02
We Think Marksans Pharma (NSE:MARKSANS) Can Manage Its Debt With Ease

Marksans Pharma (NSE:MARKSANS) Seems To Use Debt Quite Sensibly

Jun 21
Marksans Pharma (NSE:MARKSANS) Seems To Use Debt Quite Sensibly

Robust Earnings May Not Tell The Whole Story For Marksans Pharma (NSE:MARKSANS)

Nov 17
Robust Earnings May Not Tell The Whole Story For Marksans Pharma (NSE:MARKSANS)

This Is The Reason Why We Think Marksans Pharma Limited's (NSE:MARKSANS) CEO Deserves A Bump Up To Their Compensation

Sep 16
This Is The Reason Why We Think Marksans Pharma Limited's (NSE:MARKSANS) CEO Deserves A Bump Up To Their Compensation

Marksans Pharma (NSE:MARKSANS) Is Increasing Its Dividend To ₹0.25

Sep 01
Marksans Pharma (NSE:MARKSANS) Is Increasing Its Dividend To ₹0.25

Marksans Pharma (NSE:MARKSANS) Could Easily Take On More Debt

Jun 14
Marksans Pharma (NSE:MARKSANS) Could Easily Take On More Debt

Is Now The Time To Put Marksans Pharma (NSE:MARKSANS) On Your Watchlist?

May 27
Is Now The Time To Put Marksans Pharma (NSE:MARKSANS) On Your Watchlist?

Is Marksans Pharma (NSE:MARKSANS) A Risky Investment?

Feb 19
Is Marksans Pharma (NSE:MARKSANS) A Risky Investment?

Marksans Pharma Limited's (NSE:MARKSANS) Stock's On An Uptrend: Are Strong Financials Guiding The Market?

Feb 04
Marksans Pharma Limited's (NSE:MARKSANS) Stock's On An Uptrend: Are Strong Financials Guiding The Market?

Here's Why We Think Marksans Pharma (NSE:MARKSANS) Is Well Worth Watching

Jan 20
Here's Why We Think Marksans Pharma (NSE:MARKSANS) Is Well Worth Watching

Do Institutions Own Marksans Pharma Limited (NSE:MARKSANS) Shares?

Jan 05
Do Institutions Own Marksans Pharma Limited (NSE:MARKSANS) Shares?

Revenue & Expenses Breakdown

How Marksans Pharma makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

NSEI:MARKSANS Revenue, expenses and earnings (INR Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 2423,7873,4703,3120
30 Jun 2422,6803,3383,0590
31 Mar 2421,7743,1373,0590
31 Dec 2321,0343,1642,8750
30 Sep 2319,9712,9652,7520
30 Jun 2319,1842,7432,6370
31 Mar 2318,5212,6632,5230
31 Dec 2217,8422,1232,4360
30 Sep 2216,6702,0042,3750
30 Jun 2215,7561,8472,3260
31 Mar 2214,9081,8682,2500
31 Dec 2114,0692,3672,3510
30 Sep 2114,0262,4732,2690
30 Jun 2114,0642,5182,0370
31 Mar 2113,7622,3852,0960
31 Dec 2013,8172,0181,9080
30 Sep 2013,1421,7241,8330
30 Jun 2012,2031,4761,7000
31 Mar 2011,3441,2081,7850
31 Dec 1910,4638791,7190
30 Sep 199,9728341,6770
30 Jun 1910,0997801,6310
31 Mar 1910,0018041,6590
31 Dec 189,5236661,6010
30 Sep 189,2235821,5990
30 Jun 189,2724631,4740
31 Mar 189,1273581,5340
31 Dec 178,9183431,5280
30 Sep 178,9492751,5500
30 Jun 178,0151871,4920
31 Mar 177,6721131,5470
31 Dec 167,926701,4750
30 Sep 167,9481361,4580
30 Jun 168,6994811,4240
31 Mar 168,9337851,2700
31 Dec 158,5361,0931,5850
30 Sep 158,4951,1911,3970
30 Jun 158,0451,1547280
31 Mar 157,9671,0947580
31 Dec 147,8509501,4820
30 Sep 147,4058971,1210
30 Jun 146,9147866930
31 Mar 146,3007191,0910
31 Dec 135,9501,0201,0130

Quality Earnings: MARKSANS has a high level of non-cash earnings.

Growing Profit Margin: MARKSANS's current net profit margins (14.6%) are lower than last year (14.8%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: MARKSANS's earnings have grown by 19.7% per year over the past 5 years.

Accelerating Growth: MARKSANS's earnings growth over the past year (17%) is below its 5-year average (19.7% per year).

Earnings vs Industry: MARKSANS earnings growth over the past year (17%) did not outperform the Pharmaceuticals industry 20.4%.

Return on Equity

High ROE: MARKSANS's Return on Equity (15.1%) is considered low.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/22 12:25
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2024/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Marksans Pharma Limited is covered by 6 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Ranjit KapadiaCentrum Broking Limited
Deepika MurarkaChoice Equity Broking Private Limited
Nitin AgarwalDAM Capital Advisors